Global Atlas of Head and Neck Cancer Incidence
A country-by-country answer to the question "which head and neck tumour is common here — and why?"
Head and neck cancer is not evenly distributed. GLOBOCAN 2022 combines to about 947,211 cases worldwide (ASR 9.8/100,000). Oral cavity cancer dominates South Asia, HPV-positive oropharyngeal cancer dominates North America and Northern Europe, nasopharyngeal carcinoma dominates South-East Asia and North Africa, and UV-related lip cancer dominates Australia/New Zealand and the Pacific.
Worldwide cases by subsite, 2022
| Subsite | ICD | New cases | ASR /100k | Main driver | High-incidence regions |
|---|---|---|---|---|---|
| Lip + oral cavity | C00–C06 | 389,846 | 4.0 | Tobacco, areca nut, betel quid, alcohol; UV for lip | South-Central Asia, Melanesia, Southern Africa |
| Larynx | C32 | 189,191 | 1.9 | Tobacco + heavy alcohol | Caribbean, Eastern & Southern Europe, South Asia |
| Nasopharynx | C11 | 120,434 | 1.3 | EBV, genetics, childhood salt-preserved fish | South-East Asia, southern China, North Africa |
| Oropharynx | C01, C09–C10 | 106,400 | 1.1 | Persistent HPV-16 infection (high-income countries) | North America, Northern/Western Europe, Australia/NZ |
| Hypopharynx | C12–C13 | 86,257 | 0.89 | Tobacco + alcohol, iron deficiency, malnutrition | Eastern Europe, South-Central Asia |
| Salivary glands | C07–C08 | 55,083 | 0.56 | Prior radiation, mixed/uncertain, autoimmune | Western & Central Africa (highest relative share) |
The 2026 subsite re-analysis: lip, oral cavity and pharynx
Oral cavity cancer is the largest single subsite: 317,500 cases, 41.9% of the 758,020 lip/oral/pharyngeal cancers in 2022.
| Subsite | Cases | Share of LOCP | Male ASR | Female ASR | Main driver |
|---|---|---|---|---|---|
| Oral cavity (C02–C06) | 317,500 | 41.9% | 4.6 | 2.0 | Smoked/smokeless tobacco, areca nut, alcohol |
| Oropharynx (C01, C09–C10) | 146,500 | 19.3% | 2.6 | 0.5 | HPV-16 in high-income countries |
| Nasopharynx (C11) | 120,400 | 15.9% | 1.9 | 0.7 | EBV + genetic susceptibility + diet |
| Hypopharynx (C12–C13) | 86,300 | 11.4% | 1.6 | 0.3 | Tobacco + alcohol, nutritional deficiency |
| Salivary glands (C07–C08) | 55,100 | 7.3% | 0.7 | 0.5 | Mixed; prior radiation |
| Lip (C00) | 32,200 | 4.2% | 0.5 | 0.2 | Cumulative UV radiation |
Overall head and neck cancer incidence by world region
| Region | Incidence ASR /100k | 5-year prevalence /100k | What drives the figure |
|---|---|---|---|
| Asia | 13.0 | 34.7 | Highest regional incidence; driven by oral cavity and nasopharyngeal cancers. |
| Europe | 11.3 | 69.9 | High 5-year prevalence; oropharyngeal (HPV) and laryngeal cancers are prominent. |
| Australia / New Zealand | 10.9 | 63.6 | UV-related lip cancer plus rising HPV-associated oropharyngeal cancer. |
| North America | 10.7 | 64.7 | Oropharynx is the dominant lip/oral/pharyngeal subsite among men (43.8%). |
| South America | 7.6 | 28.5 | Laryngeal and oropharyngeal cancers contribute substantially. |
| Africa | 5.3 | 8.0 | Lower recorded ASR, but NPC in North Africa and salivary gland cancers in West/Central Africa are relatively prominent. |
| Central America | 2.9 | 8.8 | Lowest recorded regional ASR; partly reflects registry coverage. |
Which tumour dominates in each region?
Use this table as the short answer to "what is the common head and neck cancer in my country?" Each row links to the corresponding topic in this knowledge base.
HPV-positive oropharyngeal cancer
North America · 43.8% of the regional lip/oral/pharyngeal burden
~70% of US oropharyngeal cancers are HPV-positive; oropharynx is the most common LOCP subsite among men.
Clinical consequence: Painless cystic neck lump in a non-smoking man aged 40–60 → FNA with p16/HPV testing, not antibiotics.
HPV-positive oropharyngeal cancer and laryngeal cancer
Northern & Western Europe / UK · HPV-attributable fraction 52–77% in the UK and Scandinavia
Denmark 63%, Sweden 72%, Norway 77%; highest oropharyngeal ASRs in men in Slovakia (11.1) and Romania (10.6).
Clinical consequence: Ask for p16 testing on every oropharyngeal SCC; note that Southern Europe has <20% HPV attribution.
Oral cavity cancer
South-Central Asia (India, Bangladesh, Pakistan, Sri Lanka) · 59.8% of the regional lip/oral/pharyngeal burden
India: 143,759 new oral cancers and 79,979 deaths in 2022 (ASR 10.1); male ASRs 11–13 across the region.
Clinical consequence: Any ulcer, white/red patch or restricted mouth opening >2–3 weeks → oral examination and biopsy.
Nasopharyngeal carcinoma
South-East Asia · 50.8% of the regional lip/oral/pharyngeal burden
Brunei ASR 6.4, Indonesia 6.1 (18,835 cases), Malaysia 5.9, Singapore 5.4, Vietnam 4.7; male ASR up to 9.6 in Indonesia.
Clinical consequence: Unilateral blocked ear, nosebleeds or upper-neck lump → nasopharyngoscopy, MRI and EBV DNA.
Nasopharyngeal carcinoma
Northern Africa & the Middle East · 41.8% of the regional lip/oral/pharyngeal burden
Algeria recorded 1,608 cases (ASR 3.5; 4.8 in men) and 971 deaths; intermediate endemic rates in Morocco, Tunisia, Egypt and Sudan.
Clinical consequence: Distinguish NPC from sinonasal cancer with endoscopy and MRI; check EBV DNA.
Laryngeal and hypopharyngeal cancer
Eastern Europe, Caribbean & Brazil · Hypopharynx 15.8% of Eastern Europe’s LOCP burden
Cuba male larynx ASR 14.8, Moldova 12.2, Romania 10.3; Bangladesh male hypopharynx ASR 9.3.
Clinical consequence: Hoarseness >2–3 weeks → laryngoscopy; ask about organ-preserving treatment options.
Lip and head/neck skin cancer; HPV-positive oropharyngeal cancer
Australia, New Zealand & the Pacific · Lip cancer 20.5% of Australia/NZ LOCP burden; 26.5% in Melanesia
Papua New Guinea male lip ASR 8.2 and female oral cavity ASR 8.1; Australia male lip ASR 3.2.
Clinical consequence: SPF lip balm, hats and skin checks; non-healing lip, ear or scalp lesion → biopsy.
Nasopharyngeal carcinoma and thyroid cancer
East Asia (incl. South Korea, China, Japan) · NPC 36.9% of the East Asian LOCP burden; Asia holds 72.7% of global thyroid cancer cases
China 51,010 NPC cases; South Korea thyroid ASR 39.5/100,000 in women, largely from overdiagnosis.
Clinical consequence: For an incidental small thyroid nodule, ask whether active surveillance is appropriate before agreeing to surgery.
Ten country-level signals worth knowing
| Country / group | Figure | What it means |
|---|---|---|
| India | 143,759 oral cancer cases / 79,979 deaths (2022) | Largest national oral cancer burden; 70–80% attributable to tobacco and areca nut. |
| United States | ≈70% of oropharyngeal cancers HPV-positive | HPV-driven disease now exceeds cervical cancer incidence among women. |
| Indonesia | 18,835 NPC cases; ASR 6.1 (9.6 in men) | Second-largest national NPC burden and one of the highest ASRs. |
| Malaysia / Brunei / Singapore | NPC ASR 5.9 / 6.4 / 5.4 | Nine of the ten highest national NPC ASRs are in South-East Asia. |
| South Korea | Thyroid ASR 39.5 in women, 7.6 in men | Highest in Asia; mostly ultrasound-driven overdiagnosis with stable low mortality. |
| Cuba / Moldova / Romania | Male larynx ASR 14.8 / 12.2 / 10.3 | Historical tobacco and alcohol exposure pattern. |
| Bangladesh | Male hypopharynx ASR 9.3; female 1.6 | Highest hypopharyngeal ASR worldwide in both sexes. |
| Papua New Guinea | Male lip ASR 8.2; female oral cavity ASR 8.1 | Among the world’s highest rates for both UV- and areca-related disease. |
| Algeria | 1,608 NPC cases; ASR 3.5 (4.8 in men) | North African endemic focus with a distinct age distribution. |
| China | 51,010 NPC cases; 27,169 male larynx cases | Largest absolute NPC burden and high-volume head and neck surgical practice. |
Caution with small populations: the Maldives has the world's highest reported nasopharyngeal cancer ASR (7.5/100,000) but only 36 cases. A high ASR built on a small denominator is statistically unstable — always read the case count next to the rate.
How to read these numbers
- ASR (age-standardised rate) removes the effect of different population age structures so countries can be compared fairly. It is a rate, not a case count.
- Case counts reflect both risk and population size. China has the largest absolute NPC burden (51,010 cases) partly because of its population, while Brunei has a much higher rate with far fewer cases.
- Registry coverage varies. Low recorded rates in some low-income regions partly reflect limited cancer registration and pathology services, not necessarily low true risk.
- Grouping differs between publications. Some tables group lip with oral cavity (C00–C06); others separate C00. The 2026 subsite analysis groups base of tongue (C01) with oropharynx. Check the ICD codes before comparing two numbers.
- Estimates, not counts. GLOBOCAN produces modelled estimates for countries without complete registration. They are the best available global picture, not a census.
The four best-documented subsites (lip/oral cavity, oropharynx, nasopharynx, larynx) together account for roughly 418,000 deaths a year in GLOBOCAN 2022 estimates.
Frequently asked questions about the global pattern
Which head and neck cancer is most common worldwide?
Cancer of the lip and oral cavity: 389,846 new cases in GLOBOCAN 2022 (ASR 4.0/100,000), about 41% of all head and neck cancers. Oral cavity cancer alone (excluding lip) accounted for 317,500 cases in the 2022 subsite analysis.
Which head and neck cancer is most common in the United States?
Oropharyngeal cancer is the dominant lip/oral/pharyngeal subsite among US men (43.8% of the regional burden), and roughly 70% of US oropharyngeal cancers are HPV-positive. This reflects the HPV-16 epidemic in high-income countries rather than tobacco.
Which head and neck cancer is most common in India?
Oral cavity cancer. India recorded 143,759 new cases and 79,979 deaths in 2022 — 10.2% of all Indian cancers — with men accounting for about 75%. Chewing tobacco, areca nut and betel quid explain most of the burden.
Why is nasopharyngeal cancer so common in South-East Asia but rare in the West?
Endemic NPC combines EBV infection with genetic susceptibility and childhood dietary exposure (salt-preserved fish). Nine of the ten highest national ASRs are in South-East Asia; the US ASR is about 0.4/100,000. Asia accounted for 83.3% of the 120,434 global cases in 2022.
Is thyroid cancer really increasing, or just being detected more?
Mainly being detected more. Incidence has climbed steeply with widespread neck ultrasound — South Korea has the highest reported ASR (39.5/100,000 in women) — while mortality has stayed low (global ASR 0.4). Overdiagnosis of small papillary cancers is the accepted explanation.
Why do head and neck cancer rates differ so much between countries?
Because the main causes are local exposures: HPV and HPV vaccination coverage, tobacco and areca nut chewing, alcohol, ultraviolet radiation, EBV and dietary patterns, occupational carcinogens, and the intensity of diagnostic imaging. Registry coverage also affects recorded rates.
How many head and neck cancers were diagnosed worldwide in 2022?
GLOBOCAN 2022 estimates combine to 947,211 cases across lip/oral cavity, salivary glands, oropharynx, nasopharynx, hypopharynx and larynx, with an overall age-standardised incidence of about 9.8 per 100,000. A separate 2026 subsite analysis counted 758,020 lip/oral cavity/pharyngeal cases, excluding the larynx.
Should where I live change which symptoms I worry about?
Yes, it changes the prior probability. A painless neck lump in North America points strongly toward HPV-positive oropharyngeal cancer; a non-healing cheek ulcer in South Asia toward oral cancer; unilateral nasal obstruction or a blocked ear in South-East Asia or North Africa toward nasopharyngeal carcinoma; and a non-healing lower-lip sore in Australia toward UV-related lip cancer.
Sources
- Global Cancer Observatory (GLOBOCAN 2022)
- Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables)
- Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022
- Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary)
- Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings)
- Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities
- Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison
- Smokeless Tobacco and Oral Cancer in Global Perspective
- Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050
- Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008
- Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII)
Medical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.